Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Cepheid, Sherlock Biosciences Partner on SARS-CoV-2 Diagnostic Test

Cepheid, Sherlock Biosciences Partner on SARS-CoV-2 Diagnostic Test

Feb 28, 2020
|
staff reporter

NEW YORK – Cepheid and Sherlock Biosciences said on Friday that they have formed a research collaboration to develop new molecular diagnostic tests, using Sherlock Biosciences' CRISPR-based engineering biology platform SHERLOCK to design tests to run on Cepheid's GeneXpert systems.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Keep It (Partly) Virtual

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

For Cross-Protection

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Proteomics of Severity

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Genome Biology Papers on Regulatory Element, Single-Cell Integration, Sequence Simulation Tools

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.

What's Popular?

In Business News

  1. Olink Files For Public Offering in US

  2. Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

  3. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

  4. Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

  5. Quidel Stock Plunges in February as GenomeWeb Index Falls 3 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.